$3.96
0.174.49%
最終更新: Oct 29, 5:16 AM
Benzinga
Benzinga
Benzinga
木曜日, 10 29
Benzinga
© 2026 Benzinga | All Rights Reserved
Aclaris Therapeutics (ACRS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.16 | $-0.16 | $-0.14 | $-0.14 |
| Actual | $-0.15 | $-0.15 | $-0.16 | $-0.12 |
| Surprise | +6.25% | +6.25% | -14.3% | +14.3% |
| Revenue | ||||
| Estimate | $1.4M | $1.3M | $2.0M | $1.5M |
| Actual | $1.6M | $2.0M | $1.3M | $3.3M |
| Surprise | +17.7% | +49.9% | -35.7% | +123.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.16 | $-0.18 | $-0.16 | $-0.15 |
| Revenue | ||||
| Consensus | $1.2M | $1.3M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.15 | $-0.16 | 6.25 % |
| Q1 | May 7, 2026 | $-0.15 | $-0.16 | 6.25 % |
| Q4 | Feb 26, 2026 | $-0.16 | $-0.14 | -14.3 % |
| Q3 | Nov 6, 2025 | $-0.12 | $-0.14 | 14.3 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $1.63M | $1.38M | 17.7 % |
| Q1 | May 7, 2026 | $2.00M | $1.33M | 49.9 % |
| Q4 | Feb 26, 2026 | $1.30M | $2.01M | -35.7 % |
| Q3 | Nov 6, 2025 | $3.30M | $1.48M | 123.0 % |